Roquefort Therapeutics plc is a material biotech company focused on next generation medicines for hard to treat cancers
2020 Company Founded
5 Pre - Clinical Programs
2021 IPO London Main Market
Read more: Suspension of Trading Pending 2022 Annual Report
Suspension of Trading Pending 2022 Annual Report
Read more: Suspension - Roquefort Therapeutics plc
Suspension - Roquefort Therapeutics plc
Read more: Confirmation of No Exposure to Silicon Valley Bank
Confirmation of No Exposure to Silicon Valley Bank
High growth oncology market
Our portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines.
The highly complementary portfolio of best-in-class medicines is focused on the cancers that remain resistant to existing therapies and creates significant upside potential in high value and high growth oncology market.
Expert leadership team with proven track record in drug development, regulatory approvals and biotech transactions.
The team includes Nobel Laureate, Professor Sir Martin Evans and experienced biotechnology CEO, Ajan Reginald.
State of the art facility
State of the art laboratory located in Stratford-upon-Avon includes a clean room, laminar flow cabinets and cryopreservation infrastructure required for pre-clinical development of innovative new medicines, particularly cell and gene therapies.
Network of partnerships with leading academic cancer research centres which complements our own world-class in-house expertise and laboratory infrastructure and enables us to implement a broader and more effective development strategy.
This distributed R&D model is highly scalable and cost effective.